Pre-exposure prophylaxis (PrEP) is the new component of HIV prevention programmes that plays a key role in the preventing transmission of HIV. PrEP is for HIV negative people and involves taking part of a treatment regimen (typically a medicine called Truvada) to stop them contracting HIV. Truvada has been licensed and recommended for people at risk of HIV in the United States since July 2012 but we still don’t have this in Europe. The European campaign has today sent a letter to Gilead Sciences calling for them to reduce the price of Truvada. The letter has been signed by a number of organisations across Europe and Russia.
“Ensuring that people have access to PrEP is essential to stopping the spread of HIV. Year on year we have seen an increase in the number of people living with HIV highlighting the need for effective prevention strategies. PrEP has been proven to be effective and must be funded in the UK and Europe and that is why I have added my signature to the letter.”
The letter calls for Gilead Sciences to take action
The PrEP now campaign is calling for Gilead Sciences the company that makes the drug Truvada to reduce the price of the drug so that this vital medicine is available to people at risk of becoming infected with HIV in the UK and Europe. PrEP provides near perfect protection when taken during periods of risk – adding this to the prevention package has had a dramatic impact on HIV rates in San Francisco.
Jason Warriner, Lead Nurse at The Sussex Beacon said:
“Signing the letter has contributed to the call to action highlighting that PrEP should be accessible to all those at risk of HIV. Research has shown that is effective method of prevention.”
The Sussex Beacon remains committed to supporting people living with HIV and responding to their changing needs.